ClinicalTrials.gg
Active, not recruitingNCT06834672Updated Sep 9, 2026

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 3 interventional study of IBI354 and paclitaxel/Gemcitabine/Liposomal doxorubicin in Ovarian, Primary Peritoneal and Fallopian Tube Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies in Fallopian Tube Neoplasms with a site in China — 33 open to participants now, 40 under way, 17 of them phase 3. Fallopian Tube Neoplasms · China.

Planned enrollment
20th of 59
450 · median 220
Started
2025
with 8 others
Phase 3
27 of 59
10 open now
Primary completion
2027-12
later than 25 of 39 live
Registered
42nd of 59
by date

Among the 59 studies in Fallopian Tube Neoplasms with a site in China, this one is the 20th largest by planned enrollment, is one of 9 that started in 2025, is one of 27 in phase 3, reaches primary completion later than 25 of the 39 other live ones, and was the 42nd registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 130 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

33 of the 59 studies in Fallopian Tube Neoplasms with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 105 Fallopian Tube Neoplasms studies recruiting now, 87 (83%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Fallopian Tube Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multiregional, multicenter, randomized, open-label, phase III study to compare the efficacy, safety, and tolerability of IBI354 monotherapy with investigator's choice of chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan) in patients with HER2-expressing, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer.

Participants with advanced ovarian, primary peritoneal, fallopian tube cancer who have failed or are intolerant to first-line or more platinum-based chemotherapy will be randomly assigned in a 2:1 ratio to two treatment arms:

Experimental Arm: IBI354 monotherapy arm, 12 mg/kg IBI354 on Day 1 of each 3-week cycle; Control Arm: Investigator's choice chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan)

03

Conditions studied

  • Ovarian
  • Primary Peritoneal
  • Fallopian Tube Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have signed the form (ICF) and are able to comply with the follow-up visits and related procedures required in the protocol.
  2. Female subjects, aged ≥ 18 years.
  3. ≥ 12 weeks.
  4. Performance Status (ECOG PS) score of 0 or 1.
  5. or cytologically confirmed locally advanced unresectable or ovarian cancer, primary peritoneal cancer, or fallopian tube cancer:

    1. expression (IHC1+, IHC2+, IHC 3+) in tumor tissues confirmed by the HER2 expression testing performed by the sponsor's designated central laboratory (hereinafter referred to as the central laboratory).Note: Subjects must provide a sufficient tumor tissue sample for central HER2 assessment.Freshly collected samples are preferred, and formalin-fixed and paraffin-embedded (FFPE) blocks are preferred.If a newly collected biopsy cannot be provided, the most recent archival sample will be required.If the subjects have previously been confirmed by the central laboratory to have HER2 expression in tumor tissues (IHC1+, IHC2+, IHC 3+), they meet the inclusion criteria and do not need to be retested.
    2. Previously received ≥ 1 line of platinum-based chemotherapy and experienced disease progression: If only received 1 line of platinum-based chemotherapy, they must have received at least 4 cycles of platinum-based therapy, have a best response of PR or CR (not required for therapy), and have experienced disease progression > 3 months and \< 6 months after the last platinum-based chemotherapy; if received 2 or more lines of platinum-based chemotherapy, they must have experienced disease progression during or \< 6 months after the last platinum-based chemotherapy.Note: Progressive disease is progressive disease shown by imaging as per v1.1.
    3. Patients must have received at least 1 line of prior systemic anti-tumor therapy:

      • Adjuvant ± neoadjuvant therapy is considered as 1 line of systemic anti-tumor treatment.
      • Maintenance therapy [e.g., bevacizumab, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor] as part of front-line anti-tumor therapy (the number of lines will not be calculated separately).
      • For a change in treatment regimen, if the changed treatment drug is the same type of drug as the previous treatment (e.g., platinum, taxane, anthracycline, PARP inhibitor, etc. before and after the change), and there is no disease progression before the change in treatment drug, the changed treatment regimen will be used as part of the number of lines of previous treatment and will not be counted separately.If the changed therapeutic drug is a different type of drug from the previous first-line treatment, or if the drug of the same type is changed after disease progression, the number of lines should be calculated separately.
      • If anti-tumor drugs are added to the original treatment regimen for combination therapy (except for maintenance treatment), the number of lines should be calculated separately.
      • The number of lines of endocrine therapy will be calculated separately unless administered as a maintenance regimen.
    4. For subjects with documented positive expression of folate receptor α (FRα) in tumor tissues [using the VENTANA FOLR1 (FOLR-2.1) RxDx assay to assess the percentage of tumor cells with moderate (grade 2) and/or strong (grade 3) membrane staining to the total number of viable tumor cells ≥ 75% based on the "PS2+" scoring method], prior treatment with mirvetuximab soravtansine (MIRV) or an ADC drug with the same target and radiographically confirmed progressive disease as per RECIST v1.1 is required.
    5. Subjects with documented BRCA mutations (germline and/or somatic) must have received prior treatment with a PARP inhibitor.This study allowed the inclusion of subjects with BRCA mutations identified during the platinum-resistant phase who were PARP inhibitor-naïve.
  6. Patients must have radiologically confirmed disease progression according to RECIST v1.1 during or after the most recent line of anti-tumor therapy.
  7. At least 1 measurable target lesion according to RECIST v1.1 [long diameter ≥ 10 mm (short diameter ≥ 15 mm for lymph node lesions) as accurately measured by computed tomography (CT) or magnetic resonance imaging (MRI, with intravenous contrast agent preferred) at baseline, and the lesion is suitable for repeated and accurate measurements].Lesions that have received prior local treatment (e.g., radiotherapy, radioactive seed implantation, and hepatic artery embolization/infusion chemotherapy) can be considered measurable target lesions only if they clearly show PD as per RECIST v1.1].
  8. (LVEF) ≥ 50% within 28 days prior to the first dose of the drug.
  9. Adequate bone marrow and organ functions, with laboratory test values meeting the following requirements within 7 days before the first dose of the study drug (If the laboratory tests performed during the screening period do not meet the requirements below, only 1 retest is allowed during the screening period.Any cell/blood component, colony stimulating factor, or cytokine therapy is not allowed within 7 days prior to the hematology test):

    1. Routine blood test: (ANC) ≥ 1.5 × 109/L or within the normal range; count (PLT) ≥ 90 × 109/L; (HGB) ≥ 90 g/L.
    2. Liver function: total (TBIL) ≤ 1.5 × (ULN); for subjects with Gilbert's syndrome, TBIL ≤ 3 × ULN; for subjects without liver metastasis, and ALT ≤ 2.5 × ULN; for subjects with liver metastasis, AST and ALT ≤ 5 × ULN, TBIL ≤ 3 × ULN; albumin (ALB) ≥ 28 g/L.
    3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN or rate (CCR) ≥ 60 mL/min (calculated using the Cockcroft-Gault formula or by measuring the volume of 24-h urine collection); urinalysis indicates urine protein \< 2+, and for subjects whose baseline urinalysis indicates urine protein ≥ 2+, 24-h urine collection should be performed and the protein content in 24-h urine should be \< 1 g (if both test methods are adopted, the measured value from 24-h urine collection will be used to determine eligibility).
    4. Coagulation function: (INR) ≤ 1.5; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  10. For female subjects of , effective measures are required throughout the treatment period and 6 months after the treatment period (see Section5.8.1.1).

Exclusion criteria

Exclusion Criteria

Subjects should not be enrolled in the study if they meet any of the following criteria:

  1. Histological or cytological examination results meet any of the following conditions:

    1. Documented sarcoma, mucinous carcinoma, undifferentiated carcinoma, or a combination.
    2. Demonstrated low-grade or borderline tumors, or both.
  2. Participation in any other interventional clinical study, except for observational (non-interventional) studies or follow-up period after the end of study treatment in interventional studies.
  3. Paclitaxel, gemcitabine, liposomal doxorubicin, and topotecan listed in the control arm are not suitable (e.g., all of the above drugs have been previously treated, without any disease response, and with disease progression within 6 months after the last dose).
  4. Prior treatment with ADC drugs with a small molecule payload of camptothecin or its derivatives.
  5. Prior to the first dose of study drug:

    1. Received systemic treatment such as intravenous infusion of chemotherapy drugs, large molecule targeted drugs, antibody-drug conjugates, immunotherapy, endocrine therapy, or cell therapy within 4 weeks; received local treatment such as intraperitoneal perfusion chemotherapy, tumor embolization, or interventional chemotherapy within 2 weeks.
    2. Received oral chemotherapy drugs, small molecule targeted drugs, and Chinese herbal medicines indicated for anti-tumor treatment within 2 weeks or 5 half-lives (whichever is longer).
    3. Radical radiotherapy within 4 weeks; palliative radiotherapy within 2 weeks.
    4. Treatment with strong inhibitors or inducers of cytochrome P450 3A4 () within 2 weeks or 5 half-lives (whichever is longer).
    5. Major surgery (craniotomy, thoracotomy or laparotomy, and other types considered by the investigator to be "major", excluding needle ) within 4 weeks, or presence of significant unhealed wounds, trauma, or ulcers; exploratory laparoscopy within 2 weeks.
    6. Live(mRNA and non-replicating adenovirus vaccines are not considered live)vaccines within 4 weeks.
  6. Patients with adverse reactions caused by previous anti-tumor treatments that have not been alleviated to grade 0 or 1 before enrollment according to v5.0 criteria [except for grade 2 alopecia, asthenia, pigmentation, insomnia, peripheral neuropathy, hypomagnesemia, and toxicities stably controlled by medication (such as hypothyroidism stably controlled by replacement therapy, and hypertension stably controlled below 160/100 mmHg after antihypertensive medication).
  7. Symptomatic central nervous system (CNS) , spinal cord compression, carcinomatous meningitis, or history of carcinoma.Subjects with asymptomatic (no neurological symptoms, no need for treatment, and the diameter of metastases is ≤ 1.5 cm) or subjects with brain metastases that are stable after treatment may be considered for inclusion in the study if they meet all of the following criteria: (1) outside the central nervous system; (2) no metastases to midbrain, pons, cerebellum, meninges, medulla oblongata, or spinal cord; (3) stable for at least 4 weeks, without new or enlarging metastases (Clinical symptoms, signs, andRadiologic evidence clearly confirmed); (4) Corticosteroids or anticonvulsants were discontinued at least 2 weeks prior to the first dose of study drug.Central nervous system lesions should be monitored and examined regularly during the study.

    Note:Central nervous system lesions will not be considered target lesions.

  8. Subjects with pneumonia requiring corticosteroid therapy, or uncontrolled lung diseases (e.g., pulmonary fibrosis, severe radiation pneumonia, and acute lung injury) or suspected to have such diseases by imaging during the screening period.
  9. Uncontrolled or significant cardiovascular and cerebrovascular diseases, including the following conditions:

    1. Uncontrolled myocarditis, or symptomatic congestive heart failure Class II-IV ( [NYHA] criteria), symptomatic or uncontrolled arrhythmias such as ventricular tachycardia, atrial fibrillation, ventricular fibrillation, torsades de pointes, etc.
    2. Fridericia- interval (QTcF) >480 ms, personal or family history of congenital long/short QT syndrome.If QTcF is > 480 ms in 1 examination during the screening period, 3 consecutive ECG examinations are required to calculate the mean QTcF value. If QTcF is still > 480 ms, the subject will not be enrolled.
    3. Before the first dose of study treatmentHistory of any arterial thromboembolic events within 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or .
    4. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolic event within 3 months prior to first dose of study intervention.Patients who have received anticoagulant therapy for 2 weeks after the discovery of deep vein thrombosis and have stable thrombosis after re-examination, or have a low risk (such as intermuscular venous thrombosis) as assessed by the investigator, are considered to meet the inclusion criteria.
    5. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) despite of standard treatment.
  10. Received within 14 days prior to the first dose of study treatment, excluding intranasal and inhaled corticosteroids, or systemic corticosteroids at doses lower than 10 mg/day of prednisone (or equivalent), or corticosteroids for preventing allergy to contrast media.
  11. Tumor invades surrounding important tissues and organs, accompanied by obvious clinical symptoms or abnormal organ functions (such as mediastinal great vessels, superior vena cava and inferior vena cava, pericardium, heart, trachea, etc.).
  12. Bleeding within 3 months prior to the first start of study treatment that is life-threatening, requiring blood transfusion or invasive treatment.
  13. Symptomatic abdominopelvic effusion requiring intervention (except abdominopelvic effusion caused by tumor as judged by the investigator), pleural effusion, or pericardial effusion (subjects with stably controlled effusion are allowed to be enrolled, defined as no significant increase in effusion under the condition of removing the drainage tube or no drainage, and no clinical symptoms, for at least 7 days).
  14. Subjects with esophageal or gastric varices requiring immediate intervention (e.g., ligation or sclerotherapy), or who are considered by the investigator or gastroenterology and hepatology experts to be at high risk for bleeding, have evidence of portal hypertension (including splenomegaly from imaging) or have a history of variceal bleeding, must undergo endoscopic assessment within 3 months prior to the first start of study treatment.
  15. Patients with unhealed gastrointestinal obstruction, perforation, or fistula, or at risk of gastrointestinal obstruction or perforation (including but not limited to acute diverticulitis and abdominal abscess), or with a history of extensive bowel resection (e.g., extensive small bowel resection accompanied by chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.Note: The digestive tract refers to the muscular tube from the oral cavity to the anal canal, including the oral cavity, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, and ileum), large intestine (cecum, appendix, colon, and rectum), and anal canal.
  16. After tracheal stent implantation; after gastrointestinal stent implantation, the subject did not resume normal diet or defecation.
  17. Subjects with biliary obstruction, unless the obstruction has been treated locally (e.g., endoscopic stenting or percutaneous transhepatic drainage), and has decreased to \< 1.5 × .
  18. Hepatic encephalopathy, hepatorenal syndrome, or cirrhosis with Class B or above.
  19. Significant malnutrition, such as malnutrition requiring intravenous nutrition.Except for patients who have resumed a normal diet prior to the first study treatment and have discontinued intravenous nutrition.
  20. Active uncontrolled infection, including the following:

    1. Infection requiring systemic antibiotic, antiviral, or antifungal therapy.
    2. (HIV) infection (HIV 1/2 Ab positive).
    3. Acute or chronic active , defined as hepatitis B surface antigen or e antigen positive (any other antibody result) or hepatitis B core antibody positive only (hepatitis B surface antibody negative and hepatitis B e antibody negative), and HBV DNA copy number ≥ 1 × 104Copy number/mL or ≥ 2000 IU/mL; or acute or chronic active , defined as hepatitis C virus (HCV) antibody positive and HCV RNA titer above the lower limit of detection.
    4. Active tuberculosis infection, or still receiving anti-tuberculosis treatment, or received anti-tuberculosis treatment within 1 year before the first dose of the study drug.
  21. Complicated with other primary or other malignancies with active or recurrent risks within 3 years prior to the first dose of study treatment, excluding radically treated basal cell carcinoma of skin, squamous cell carcinoma of skin, radically resected carcinoma in situ, and papillary thyroid carcinoma.
  22. History of immunodeficiency diseases, including congenital or acquired immunodeficiency diseases.
  23. History of allogeneic organ transplantation, bone marrow transplantation, or autologous hematopoietic stem cell transplantation (except corneal transplantation).
  24. Allergic to other anti- antibodies/ADCs, camptothecins and their derivatives, or any component of IBI354.
  25. Subjects who are pregnant or breastfeeding (may be considered if breastfeeding is discontinued), or subjects who plan to become pregnant.
  26. Presence of other acute or chronic diseases or laboratory abnormalities that may increase the risk of study participation or drug administration, interfere with the interpretation of study results, or render the subjects unsuitable for participating in the study as judged by the investigator.
  27. Subject has a neurologic, psychiatric, or social condition that would interfere with trial compliance, significantly increase the risk of adverse events, or prevent the subject from providing written .
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Drug: IBI354

  • Active comparator
    Control Arm

    Drug: paclitaxel/Gemcitabine/Liposomal doxorubicin

Interventions

  • DrugIBI354

    intravenous infusion of 12 mg/kg on Day 1 of each 3-week treatment cycle

  • Drugpaclitaxel/Gemcitabine/Liposomal doxorubicin

    Drug pages: Paclitaxel · Gemcitabine · Liposomal doxorubicin

    paclitaxel:- Usage and dosage: 80 mg/m2 administered as an intravenous infusion on Day 1 of each weekly treatment cycle。 Gemcitabine:Usage and dosage: intravenous infusion at 1000 mg/m2 on Days 1, 8 of each 3-week treatment cycle。 Liposomal doxorubicin:Usage and dosage: intravenous infusion of 40 mg/m2 on Day 1 of each 4-week treatment cycle Topotecan: 1.25 mg/m2, in 3-week cycles (Q3W), on Days 1, 2, 3, 4, and 5 of each cycle.

06

What researchers measure

Primary outcomes

  1. To compare the Progression-free survival (PFS) of IBI354 monotherapy versus investigator's choice of chemotherapy

    PFS as evaluated per the RECIST v1.1 criteria

    Time frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)

  2. Overall Survival (OS)

    Overall survival

    Time frame: From date of randomization until the date of death from any cause (up to approximately 48 months)

Secondary outcomes

  1. Number of subjects with clinically significant changes in physical examination results

    Time frame: up to approximately 36 months

  2. Numbers of subjects with adverse events

    Time frame: up to approximately 36 months

  3. CA-125 response rate according to Gynecologic Cancer Intergroup (GCIG) criteria.

    Time frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)

  4. To compare the objective response rate (ORR) of IBI354 monotherapy versus investigator's choice of chemotherapy

    ORR as evaluated per the RECIST v1.1 criteria

    Time frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)

  5. Disease Control Rate (DCR) of IBI354 monotherapy versus investigator's choice of chemotherapy

    DCR as evaluated per the RECIST v1.1 criteria

    Time frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)

  6. Duration of Response (DoR) of IBI354 monotherapy versus investigator's choice of chemotherapy

    DoR as evaluated per the RECIST v1.1 criteria

    Time frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)

  7. Time to Response (TTR) of IBI354 monotherapy versus investigator's choice of chemotherapy

    TTR as evaluated per the RECIST v1.1 criteria

    Time frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)

  8. Numbers of subjects with adverse Event of Special Interest

    Time frame: up to approximately 36 months

  9. Numbers of subjects with Serious Adverse Event (SAE)

    Time frame: up to approximately 36 months

  10. Evaluate participant's global health status

    Evaluate participant's global health status by Quality of Life-5 Dimension-5 Level (EQ-5D-5L)

    Time frame: up to approximately 36 months

  11. Evaluate participant's cancer-related symptoms and quality of life

    Evaluate participant's cancer-related symptoms and quality of life by European by Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire-Core 30 (QLQ-C30)

    Time frame: up to approximately 36 months

  12. Evaluate the impact of ovarian cancer on participant's physiological, emotional, and social aspects

    Evaluate the impact of ovarian cancer on participant's physiological, emotional, and social aspects by EORTC Quality of Life Questionnaire-Ovarian Cancer 28 (QLQ-OV28)

    Time frame: up to approximately 36 months

  13. Pharmacokinetic (PK) paramenter of IBI354: Plasma concentration (Cmax)

    Evaluation of the plasma concentration (Cmax) in subjects treated with IBI354

    Time frame: up to approximately 36 months

  14. PK paramenter of IBI354: Area under the curve (AUC)

    Evaluation of the Area under the curve (AUC) in subjects treated with IBI354

    Time frame: up to approximately 36 months

  15. PK paramenter of IBI354: Time to maximum concentration (Tmax)

    Evaluation of the Time to maximum concentration (Tmax) in subjects treated with IBI354

    Time frame: up to approximately 36 months

  16. PK paramenter of IBI354: Clearance (CL)

    Evaluation of the Clearance (CL) in subjects treated with IBI354

    Time frame: up to approximately 36 months

  17. PK paramenter of IBI354: Volume of distribution (V)

    Evaluation of the Volume of distribution (V) in subjects treated with IBI354

    Time frame: up to approximately 36 months

  18. PK paramenter of IBI354: Half-life (T1/2)

    Evaluation of the Half-life (T1/2) in subjects treated with IBI354

    Time frame: up to approximately 36 months

  19. Immunogenicity of IBI354: the incidence of anti-drug Antibody(ADA)

    The proportion of evaluable subjects (those with both baseline and post-baseline ADA measurements) who tested positive for anti-drug antibodies.

    Time frame: up to approximately 36 months

  20. Immunogenicity of IBI354: the incidence of Neutralizing Antibody (Nab) (if applicable)

    The proportion of evaluable subjects (those with both baseline and post-baseline ADA measurements) who tested positive for neutralizing antibodies.

    Time frame: up to approximately 36 months

  21. Effect of ADA on safety (if applicable)

    Assessment of the potential impact of ADA on safety by comparing the incidence of treatment-emergent adverse events (e.g., TEAEs) between ADA-positive and ADA-negative groups.

    Time frame: up to approximately 36 months

  22. Effect of ADA on efficacy (if applicable)

    Assessment of the potential impact of ADA on drug efficacy by comparing primary efficacy endpoints (e.g., PFS, OS) between ADA-positive and ADA-negative groups.

    Time frame: up to approximately 36 months

  23. Effect of ADA on PK parameters (if applicable)

    Assessment of the potential impact of ADA on the PK parameters of IBI354 between ADA-positive and ADA-negative groups.

    Time frame: up to approximately 36 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 54 phase 3 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 109. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 19, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Dec 28, 2027
CompletionEst.
Nov 28, 2029
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06834672
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Mar 17, 2025
Primary completion
Dec 28, 2027 (estimated)
Completion
Nov 28, 2029 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2 Antibody-drug Conjugate IBI354

Start the discussion